Pharmaceutical

Lilly strikes deal with QurAlis for preclinical ALS candidate

QRL-204 is designed to restore UNC13A function, a gene identified as a risk factor in neurodegenerative diseases including ALS and dementia.

Jun 4, 2024 - 04:00
Lilly strikes deal with QurAlis for preclinical ALS candidate
QRL-204 is designed to restore UNC13A function, a gene identified as a risk factor in neurodegenerative diseases including ALS and dementia.
Read the original article

Tags:

Previous Article

ASCO 2024: Tagrisso approaches standard of Care status for NSCLC

Next Article

GRIT and Quangang announce IL-2 T-cell therapy partnership

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Early findings in gene therapy death suggest CRISPR was not the cause

STAT+: Early findings in gene therapy death suggest CRI...

Apr 27, 2023

Bayer wins FDA breakthrough therapy designation for NSCLC candidate

Bayer wins FDA breakthrough therapy designation for NSC...

Feb 26, 2024

Risk adjusted net present value: What is the current va...

Feb 6, 2024